The use of simvastatin in rabbit posterolateral lumbar intertransverse process spine fusion

Spine Journal

Volumn 6, Issue 4, 2006, Pages 391-396

  Yee, Albert Juang Ming ^a,b   Bae, Hyun W ^a   Friess, Darin ^a   Roth, Sandie M ^b   Whyne, Cari ^b   Robbin, Mark ^c   Johnstone, Brian ^a   Yoo, Jung U ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Martin Orthopaedics Biomechanics Laboratory   (Canada)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone healing; Spine; Spine fusion

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CALCIUM; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHORUS; SIMVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE GRAFT; BONE MASS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; EUTHANASIA; ILIAC CREST; LIPID BLOOD LEVEL; LUMBAR SPINE; NONHUMAN; PALPATION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RABBIT; SPINE FUSION; SPINE RADIOGRAPHY; STATISTICAL SIGNIFICANCE; VOLUMETRY;

ANIMALS; CHOLESTEROL; DISEASE MODELS, ANIMAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUMBAR VERTEBRAE; OSTEOPOROSIS; PALPATION; RABBITS; SIMVASTATIN; SPINAL FUSION; TRIGLYCERIDES;

EID: 33745551097     PISSN: 15299430     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spinee.2005.10.017     Document Type: Article

References (49)

1. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., and Jick H. Statin drugs and the risk of fracture. JAMA 284 (2000) 1921-1922
2. Chan K.A., Andrade S.E., Boles M., et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355 (2000) 2185-2188
3. Hennessy S., and Strom B.L. Statins and fracture risk. JAMA 285 (2001) 1888-1889
4. van Staa T.P., Wegman S., de Vries F., Leufkens B., and Cooper C. Use of statins and risk of fractures. JAMA 285 (2001) 1850-1855
5. Wang P.S., Solomon D.H., Mogun H., and Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283 (2000) 3211-3216
6. Edwards C.J., Hart D.J., and Spector T.D. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355 (2000) 2218-2219
7. Sugiyama M., Kodama T., Konishi K., Abe K., Asami S., and Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 271 (2000) 688-692
8. Stein E.A., Farnier M., Waldstreicher J., and Mercuri M. Effects of statins on biomarkers of bone metabolism: a randomised trial. Nutr Metab Cardiovasc Dis 11 (2001) 84-87
9. Maeda T., Matsunuma A., Kawane T., and Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 280 (2001) 874-877
10. Mundy G., Garrett R., Harris S., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286 (1999) 1946-1949
11. Skoglund B., Forslund C., and Aspenberg P. Simvastatin improves fracture healing in mice. J Bone Miner Res 17 (2002) 2004-2008
12. Curylo L.J., Johnstone B., Petersilge C.A., Janicki J.A., and Yoo J.U. Augmentation of spinal arthrodesis with autologous bone marrow in a rabbit posterolateral spine fusion model. Spine 24 (1999) 434-438 discussion 438-9
13. Nakahara K., Kuriyama M., Sonoda Y., et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol 152 (1998) 99-106
14. Sonoda Y., Gotow T., Kuriyama M., Nakahara K., Arimura K., and Osame M. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve 17 (1994) 891-897
15. Alegret M., Verd J.C., Diaz C., et al. Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits. Eur J Pharmacol 347 (1998) 283-291
16. Fukami M., Maeda N., Fukushige J., et al. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med (Berl) 193 (1993) 263-273
17. Nakahara K., Kuriyama M., Yoshidome H., et al. Experimental simvastatin-induced myopathy in rabbits. J Neurol Sci 113 (1992) 114-117
18. Behrens-Baumann W., and Thiery J. Cataracts by lipid lowering drugs? Three different HMG-CoA reductase inhibitors studied in hypercholesterolemic rabbits. Res Exp Med (Berl) 192 (1992) 7-11
19. Cheng H., Schwartz M.S., Vickers S., et al. Metabolic disposition of simvastatin in patients with T-tube drainage. Drug Metab Dispos 22 (1994) 139-142
20. Gerson R.J., MacDonald J.S., Alberts A.W., et al. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am J Med 87 (1989) 28S-38S
21. Kobayashi M., Ishida F., Takahashi T., et al. Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits. Jpn J Pharmacol 49 (1989) 125-133
22. Bolego C., Baetta R., Bellosta S., Corsini A., and Paoletti R. Safety considerations for statins. Curr Opin Lipidol 13 (2002) 637-644
23. Omar M.A., Wilson J.P., and Cox T.S. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35 (2001) 1096-1107
24. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
25. Phillips A. The Fracture Intervention Trial. Lancet 349 (1997) 505-506
26. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 359 (2002) 2018-2026
27. Riggs B.L., and Hartmann L.C. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 348 (2003) 618-629
28. Siris E., Adachi J.D., Lu Y., et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporos Int 13 (2002) 907-913
29. Tremollieres F., and Lopes P. [Specific estrogen receptor modulators (SERMs)]. Presse Med 31 (2002) 1323-1328
30. Chan M.H., Mak T.W., Chiu R.W., Chow C.C., Chan I.H., and Lam C.W. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab 86 (2001) 4556-4559
31. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., and Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283 (2000) 3205-3210
32. Pasco J.A., Kotowicz M.A., Henry M.J., Sanders K.M., and Nicholson G.C. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 162 (2002) 537-540
33. Wada Y., Nakamura Y., and Koshiyama H. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 160 (2000) 2865
34. Ishida F., Watanabe K., Sato A., et al. Comparative effects of simvastatin (MK-733) and pravastatin (CS-514) on hypercholesterolemia induced by cholesterol feeding in rabbits. Biochim Biophys Acta 1042 (1990) 365-373
35. Vickers S., Duncan C.A., Chen I.W., Rosegay A., and Duggan D.E. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 18 (1990) 138-145
36. Seeherman H., Wozney J., and Li R. Bone morphogenetic protein delivery systems. Spine 27 (2002) S16-S23
37. Kandziora F., Schmidmaier G., Schollmeier G., et al. IGF-I and TGF-beta1 application by a poly-(D,L-lactide)-coated cage promotes intervertebral bone matrix formation in the sheep cervical spine. Spine 27 (2002) 1710-1723
38. Kandziora F., Bail H., Schmidmaier G., et al. Bone morphogenetic protein-2 application by a poly(D,L-lactide)-coated interbody cage: in vivo results of a new carrier for growth factors. J Neurosurg 97 (2002) 40-48
39. King G.N. The importance of drug delivery to optimize the effects of bone morphogenetic proteins during periodontal regeneration. Curr Pharm Biotechnol 2 (2001) 131-142
40. Boden S.D., Schimandle J.H., and Hutton W.C. Lumbar intertransverse-process spinal arthrodesis with use of a bovine bone-derived osteoinductive protein: a preliminary report. J Bone Joint Surg Am 77 (1995) 1404-1417
41. Boden S.D., Schimandle J.H., and Hutton W.C. An experimental lumbar intertransverse process spinal fusion model: radiographic, histologic, and biomechanical healing characteristics. Spine 20 (1995) 412-420
42. Boden S.D., Schimandle J.H., Hutton W.C., et al. In vivo evaluation of a resorbable osteoinductive composite as a graft substitute for lumbar spinal fusion. J Spinal Disord 10 (1997) 1-11
43. Ishikawa S., Shin H.D., Bowen J.R., and Cummings R.J. Is it necessary to decorticate segmentally instrumented spines to achieve fusion?. Spine 19 (1994) 1686-1690
44. Martin Jr. G.J., Boden S.D., Titus L., and Scarborough N.L. New formulations of demineralized bone matrix as a more effective graft alternative in experimental posterolateral lumbar spine arthrodesis. Spine 24 (1999) 637-645
45. Morone M.A., and Boden S.D. Experimental posterolateral lumbar spinal fusion with a demineralized bone matrix gel. Spine 23 (1998) 159-167
46. Schimandle J.H., Boden S.D., and Hutton W.C. Experimental spinal fusion with recombinant human bone morphogenetic protein-2. Spine 20 (1995) 1326-1337
47. Silcox III D.H., Boden S.D., Schimandle J.H., Johnson P., Whitesides T.E., and Hutton W.C. Reversing the inhibitory effect of nicotine on spinal fusion using an osteoinductive protein extract. Spine 23 (1998) 291-296 discussion 297
48. Silcox III D.H., Daftari T., Boden S.D., Schimandle J.H., Hutton W.C., and Whitesides Jr. T.E. The effect of nicotine on spinal fusion. Spine 20 (1995) 1549-1553
49. Boden S.D., Martin Jr. G.J., Morone M., Ugbo J.L., Titus L., and Hutton W.C. The use of coralline hydroxyapatite with bone marrow, autogenous bone graft, or osteoinductive bone protein extract for posterolateral lumbar spine fusion. Spine 24 (1999) 320-327